| ó㳺íà íàñåëåíèõ ì³ñöü | ISSN: 2707-0441 eISSN: 2707-045X |
Âèïóñê 74, 2024 - Ñòîð³íêè: 150-161
ÐÎÇÏÎÂÑÞÄÆÅͲÑÒÜ ÊÎÐÎÍÀ²ÐÓÑÍί ²ÍÔÅÊÖ²¯ ÑÅÐÅÄ ÍÀÑÅËÅÍÍß ÇÀÏÎвÇÜÊί ÎÁËÀÑÒ²
Òèùåíêî Ò.Ì.1, Ñåâàëüíºâ À.².2
1 ÄÓ "ÇÀÏÎвÇÜÊÈÉ ÎÖÊÏÕ ÌÎÇ"
2 ÇÄÌÔÓ
2 ÇÄÌÔÓ
ÓÄÊ: 616.98:578.834COV]-036.2-084(477.64)
ÀÍÎÒÀÖ²ß:
Ìåòà. Àíàë³ç çàõâîðþâàíîñò³ íàñåëåííÿ Çàïîð³çüêî¿ îáëàñò³ íà ÑÎVID-19 ïðîòÿãîì 2020-2023 ðð., âèÿâëåííÿ îñîáëèâîñòåé ðîçïîâñþäæåíîñò³ âèïàäê³â ó ð³çíèõ ðàéîíàõ òà ì³ñòàõ, âñòàíîâëåííÿ ãåíäåðíèõ òà â³êîâèõ ðîçá³æíîñòåé.
Ìàòåð³àëè ³ ìåòîäè. Ïðîâåäåíî ðåòðîñïåêòèâíèé åï³äåì³îëîã³÷íèé àíàë³ç çàõâîðþâàíîñò³ íàñåëåííÿ íà ãîñòðó ðåñï³ðàòîðíó õâîðîáó, ñïðè÷èíåíó êîðîíàâ³ðóñîì SARS-CoV-2 ó Çàïîð³çüê³é îáëàñò³ ó 2020-2023 ðð. Âèêîðèñòàí³ äàí³ ³íôîðìàö³éíî¿ áàçè ñèñòåìè åï³äíàãëÿäó Å˲ÑÑÇ òà ôîðìè ¹1 «Çâ³ò ïðî îêðåì³ ³íôåêö³¿ òà ïàðàçèòàðí³ çàõâîðþâàííÿ».
Ðåçóëüòàòè äîñë³äæåííÿ òà ¿õ îáãîâîðåííÿ. Íà ï³äñòàâ³ äàíèõ ³íôîðìàö³éíî¿ áàçè ñèñòåìè åï³äíàãëÿäó Å˲ÑÑÇ òà ôîðìè ¹1 «Çâ³ò ïðî îêðåì³ ³íôåêö³¿ òà ïàðàçèòàðí³ çàõâîðþâàííÿ» ïðîâåäåíî àíàë³ç âèïàäê³â íà ÑÎVID-19 ñåðåä íàñåëåííÿ Çàïîð³çüêî¿ îáëàñò³ çà â³êîâèìè ãðóïàìè òà ñòàòòþ ç 2020 ïî 2023 ðð. Ùîì³ñÿ÷íèé ðîçïîä³ë âèïàäê³â ñåðåä íàñåëåííÿ º ð³çíîñïðÿìîâàíèì, ìàâ ï³êîâ³ ïåð³îäè, ÿê³ ÷åðãóâàëèñÿ ç³ ñïàäàìè. Âèçíà÷åíî, ùî ìàêñèìàëüíà ê³ëüê³ñòü âèïàäê³â ïðèõîäèëàñü íà 2021 ð. – 52,8%, íà 2020 ð. òà 2022 ð. – ïî 22,5%, ó 2023 ð. – 2,3%.
Ðîçïîä³ë âèïàäê³â COVID-19 ñåðåä íàñåëåííÿ çà â³êîâèìè ãðóïàìè ñâ³ä÷èòü íà çàãàëüíó òåíäåíö³þ, ùî çàô³êñîâàíà ÂÎÎÇ, à ñàìå: íà â³êîâó ãðóïó 30-79 ðîê³â ïðèïàäàâ íàéá³ëüøèé â³äñîòîê ñåðåä óñ³õ âèïàäê³â – 84,0%, äî 9 ðîê³â âêëþ÷íî – 2,4%, 10-17 ðîê³â – 4,0%, 18-29 – 9,6%. Àëå ó 2022 ð. â³äáóëèñÿ çì³íè ó á³ê ï³äâèùåííÿ ñåðåä ìîëîäøèõ ãðóï 0-9 ðîê³â äî 6,7% òà 10-17 ðîê³â äî 8,1% ïðè ñòàá³ëüíîìó çíà÷åíí³ ó â³êîâ³é ãðóï³ 18-29 ðîê³â (9,5%) òà çìåíøåíí³ íà 8,0% ó ãðóï³ 30-79 ðîê³â (75,7%).
Âèñíîâêè. Ïðîâåäåí³ äîñë³äæåííÿ äîçâîëèëè âèÿâèòè íåîäíàêîâèé ðîçïîä³ë âèïàäê³â ïî ðàéîíàì òà ì³ñòàì Çàïîð³çüêî¿ îáëàñò³: 47,1% ïðèïàäàëè íà ì. Çàïîð³ææÿ, 22,7% – íà ì. Ìåë³òîïîëü (7,0%), ì. Áåðäÿíñüê (6,7%) òà ì. Åíåðãîäàð (9,0%), 30,2% – íà ³íø³ ðàéîíè Çàïîð³çüêî¿ îáëàñò³, à íàéâèùèé ð³âåíü ñòàá³ëüíî ô³êñóâàâñÿ â ì. Åíåðãîäàð³ (â³ä 7550,20 âèï./100 òèñ. íàñ. äî 9653,89 âèï./100 òèñ. íàñ.).
Íàéá³ëüø³ ïîêàçíèêè çàõâîðþâàíîñò³ òðàäèö³éíî çàô³êñîâàíî ó â³êîâèõ ãðóïàõ 30-64 ðîêè ³ ó ÷îëîâ³ê³â (3563,22 âèï./100 òèñ. íàñ.) ³ ó æ³íîê (4894,57 âèï./100 òèñ. íàñ.), àëå ó æ³íîê ¿õ çíà÷åííÿ áóëî ó 1,5 ðàçè âèùèì (p<0,001). Ó 2021 ð. ³ ó ÷îëîâ³ê³â ³ ó æ³íîê ïîêàçíèêè çàõâîðþâàíîñò³ çðîñëè ïî âñ³ì â³êîâèì ãðóïàì ç êðàòí³ñòþ ïåðåâèùåíü 2,7-2,9 ðàçè. Ïðîòå, ó 2021-2022 ðð. ñïîñòåðåæåíü ó ÷îëîâ³ê³â íàéá³ëüø³ çíà÷åííÿ áóëè çàðåºñòðîâàí³ ó â³êîâ³é ãðóï³ 65 òà ñòàðø³ (10939,63 òà 3539,40 âèï./100 òèñ. íàñ.), à ó æ³íîê - ó â³êîâ³é ãðóï³ 30-64 ðð. (9928,89 òà 4148,87 âèï./100 òèñ. íàñ.).
Ìàòåð³àëè ³ ìåòîäè. Ïðîâåäåíî ðåòðîñïåêòèâíèé åï³äåì³îëîã³÷íèé àíàë³ç çàõâîðþâàíîñò³ íàñåëåííÿ íà ãîñòðó ðåñï³ðàòîðíó õâîðîáó, ñïðè÷èíåíó êîðîíàâ³ðóñîì SARS-CoV-2 ó Çàïîð³çüê³é îáëàñò³ ó 2020-2023 ðð. Âèêîðèñòàí³ äàí³ ³íôîðìàö³éíî¿ áàçè ñèñòåìè åï³äíàãëÿäó Å˲ÑÑÇ òà ôîðìè ¹1 «Çâ³ò ïðî îêðåì³ ³íôåêö³¿ òà ïàðàçèòàðí³ çàõâîðþâàííÿ».
Ðåçóëüòàòè äîñë³äæåííÿ òà ¿õ îáãîâîðåííÿ. Íà ï³äñòàâ³ äàíèõ ³íôîðìàö³éíî¿ áàçè ñèñòåìè åï³äíàãëÿäó Å˲ÑÑÇ òà ôîðìè ¹1 «Çâ³ò ïðî îêðåì³ ³íôåêö³¿ òà ïàðàçèòàðí³ çàõâîðþâàííÿ» ïðîâåäåíî àíàë³ç âèïàäê³â íà ÑÎVID-19 ñåðåä íàñåëåííÿ Çàïîð³çüêî¿ îáëàñò³ çà â³êîâèìè ãðóïàìè òà ñòàòòþ ç 2020 ïî 2023 ðð. Ùîì³ñÿ÷íèé ðîçïîä³ë âèïàäê³â ñåðåä íàñåëåííÿ º ð³çíîñïðÿìîâàíèì, ìàâ ï³êîâ³ ïåð³îäè, ÿê³ ÷åðãóâàëèñÿ ç³ ñïàäàìè. Âèçíà÷åíî, ùî ìàêñèìàëüíà ê³ëüê³ñòü âèïàäê³â ïðèõîäèëàñü íà 2021 ð. – 52,8%, íà 2020 ð. òà 2022 ð. – ïî 22,5%, ó 2023 ð. – 2,3%.
Ðîçïîä³ë âèïàäê³â COVID-19 ñåðåä íàñåëåííÿ çà â³êîâèìè ãðóïàìè ñâ³ä÷èòü íà çàãàëüíó òåíäåíö³þ, ùî çàô³êñîâàíà ÂÎÎÇ, à ñàìå: íà â³êîâó ãðóïó 30-79 ðîê³â ïðèïàäàâ íàéá³ëüøèé â³äñîòîê ñåðåä óñ³õ âèïàäê³â – 84,0%, äî 9 ðîê³â âêëþ÷íî – 2,4%, 10-17 ðîê³â – 4,0%, 18-29 – 9,6%. Àëå ó 2022 ð. â³äáóëèñÿ çì³íè ó á³ê ï³äâèùåííÿ ñåðåä ìîëîäøèõ ãðóï 0-9 ðîê³â äî 6,7% òà 10-17 ðîê³â äî 8,1% ïðè ñòàá³ëüíîìó çíà÷åíí³ ó â³êîâ³é ãðóï³ 18-29 ðîê³â (9,5%) òà çìåíøåíí³ íà 8,0% ó ãðóï³ 30-79 ðîê³â (75,7%).
Âèñíîâêè. Ïðîâåäåí³ äîñë³äæåííÿ äîçâîëèëè âèÿâèòè íåîäíàêîâèé ðîçïîä³ë âèïàäê³â ïî ðàéîíàì òà ì³ñòàì Çàïîð³çüêî¿ îáëàñò³: 47,1% ïðèïàäàëè íà ì. Çàïîð³ææÿ, 22,7% – íà ì. Ìåë³òîïîëü (7,0%), ì. Áåðäÿíñüê (6,7%) òà ì. Åíåðãîäàð (9,0%), 30,2% – íà ³íø³ ðàéîíè Çàïîð³çüêî¿ îáëàñò³, à íàéâèùèé ð³âåíü ñòàá³ëüíî ô³êñóâàâñÿ â ì. Åíåðãîäàð³ (â³ä 7550,20 âèï./100 òèñ. íàñ. äî 9653,89 âèï./100 òèñ. íàñ.).
Íàéá³ëüø³ ïîêàçíèêè çàõâîðþâàíîñò³ òðàäèö³éíî çàô³êñîâàíî ó â³êîâèõ ãðóïàõ 30-64 ðîêè ³ ó ÷îëîâ³ê³â (3563,22 âèï./100 òèñ. íàñ.) ³ ó æ³íîê (4894,57 âèï./100 òèñ. íàñ.), àëå ó æ³íîê ¿õ çíà÷åííÿ áóëî ó 1,5 ðàçè âèùèì (p<0,001). Ó 2021 ð. ³ ó ÷îëîâ³ê³â ³ ó æ³íîê ïîêàçíèêè çàõâîðþâàíîñò³ çðîñëè ïî âñ³ì â³êîâèì ãðóïàì ç êðàòí³ñòþ ïåðåâèùåíü 2,7-2,9 ðàçè. Ïðîòå, ó 2021-2022 ðð. ñïîñòåðåæåíü ó ÷îëîâ³ê³â íàéá³ëüø³ çíà÷åííÿ áóëè çàðåºñòðîâàí³ ó â³êîâ³é ãðóï³ 65 òà ñòàðø³ (10939,63 òà 3539,40 âèï./100 òèñ. íàñ.), à ó æ³íîê - ó â³êîâ³é ãðóï³ 30-64 ðð. (9928,89 òà 4148,87 âèï./100 òèñ. íàñ.).
ÊËÞ×β ÑËÎÂÀ:
ÑÎVID-19, êîðîíàâ³ðóñíà ³íôåêö³ÿ, ïðîô³ëàêòèêà, ãðóïè ðèçèêó, ñòóï³íü òÿæêîñò³, êî-ìîðá³äíà ïàòîëîã³ÿ.
˲ÒÅÐÀÒÓÐÀ:
1. Andreychyn MA, Nychyk NA., Zavidniuk NH, Iosyk IaI, Ischuk IS, Ivakhiv OL. [COVID-19: Epidemiology, clinics, diagnosis, treatment and prevention]. Infectious Diseases. 2020;2(100):41-55. Ukrainian. doi: https://doi.org/10.11603/1681-2727.2020.2.11285
2. Komisarenko SV. [Scientist’s pursuit for coronavirus SARS-COV-2, which causes COVID-19: scientific strategies against pandemic]. Visnyk of the National Academy of Sciences of Ukraine. 2020;8:29-71. Ukrainian. doi: https://doi.org/10.15407/visn2020.08.029
3. Zhengli SA. Pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature Journal. 2020;579(7798):270-3. doi: https://doi.org/10.1038/s41586-020-2012-7
4. Ren LL, Wang YM., Wu ZQ, Xiang ZC, Guo L, Xu T, & Li H. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Medical Journal. 2020;133(9):1015-24. doi: https://doi.org/10.1097/CM9.0000000000000722
5. Oudkerk M, Buller HR, Kuijpers D et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology. 2020;297(1):E216-E222. doi: https://doi.org/10.1148/radiol.2020201629
6. World Health Organization. 2020. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease issuspected. Clinical management of severe acute respiratory infection (ýSARI)ý when COVID-19 disease is suspected: interim guidance, 13 March 2020. doi: https://doi.org/10.15557/PiMR.2020.0003
7. Riabokon OV, Furyk OO, Kalashnyk KV. [A case of severe COVID-19 and influenza co-infection]. Zaporozhye Medical Journal. 2023;25(5):477-82. Ukrainian. doi: https://doi.org/10.14739/2310-1210.2023.5.277452
8. Riabokon OV, Cherkaskyi VV, Kuliesh IO, Riabokon YuYu. [Dynamics of hemocoagulation and the incidence of fatal thrombotic complications in the critical course of the COVID-19 coronavirus disease]. Proceedings of the Conference. Emergency Medicine. 2022;18(4):85-6. Ukrainian. doi: https://doi.org/10.22141/2224-0586.18.4.2022.1503
9. Abere WA, Zerko WB, Yohannes MF, Habtamu SM, Hailemichae KA, Chilot KM. Global prevalence of COVID-19-induced acute respiratory distress syndrome: systematic review and meta-analysis. Systematic Reviews 2023;12(1):212. doi: https://doi.org/10.1186/s13643-023-02377-0
10. Klompas M, Baker MA, Rhee Ch. Airborne Transmission of SARS-CoV-2: Theoretical Considerations and Available Evidence. JAMA. 2020;324(5):441-2. doi: https://doi.org/10.1001/jama.2020.12458
11. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann. Intern. Med. 2020;174(1):69-79. doi: https://doi.org/10.7326/M20-5008
12. C Wu X, Chen YCai et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine. 2020;180(7):934-43. doi: https://doi.org/10.1001/jamainternmed.2020.0994
13. Wolfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9. doi: https://doi.org/10.1038/s41586-020-2196
14. Onder G, Rezza G, Brusaferro S et al. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama. 2020;323(18):1775-6. doi: https://doi.org/10.1001/jama.2020.4683
15. Xie J, Tong Z, Guan X. et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive care medicine. 2020;46(5):837-40. doi: https://doi.org/10.1007/s00134-020-05979-7
16. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. doi: https://doi.org/10.1001/jama.2020.1585
17. Centers for Disease Control and Prevention. Infection. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection. Available from: https://www.cdc.gov/covid/php/lab/index.html
ÄËß ÖÈÒÓÂÀÍÍß:
Òèùåíêî Ò.Ì., Ñåâàëüíºâ À.². Ðîçïîâñþäæåí³ñòü êîðîíàâ³ðóñíî¿ ³íôåêö³¿ ñåðåä íàñåëåííÿ Çàïîð³çüêî¿ îáëàñò³. ó㳺íà íàñåëåíèõ ì³ñöü : çá. íàóê. ïð. Ê., 2024. Âèï. 74. Ñ. 150-161.